Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Allergan Showcases Commitment to Eye Care Innovation with New Data Presentations at the Retina Society 49th Annual Scientific Meeting in San Diego

Allergan plc
Posted on: 13 Sep 16

PR Newswire

DUBLIN, Sept. 13, 2016

DUBLIN, Sept. 13, 2016 /PRNewswire/-- Allergan (NYSE: AGN) today announced that its data will be presented during the Retina Society 49th Annual Scientific Meeting in San Diego, CA, September 14-17, 2016.

Logo -

The scheduled times (noted in local Pacific Time) of the two Allergan presentations and locations at the U.S. Grant Hotel are as follows:

  • Predicting Visual Acuity Response to Anti-VEGF DME Therapy in Protocol I: A Post-hoc Analysis of Outcomes in Patient with Limited (<5 letter) and Intermediate (5-9 letter) Response at 12 Weeks
    • Date and Time:Thursday, September 15, 2016, 8:06 AM-8:12 AM
    • Categories: Diabetic Retinopathy
    • Presenter:Victor Gonzalez, MD
  • Evaluating Intravitreal Brimonidine Tartrate Drug Delivery System (Brimonidine DDS) in Patients with Geographic Atrophy in a Phase 2 Study
    • Date and Time:Friday, September 16, 2016, 9:06 AM-9:12 AM
    • Categories: Age-Related Macular Degeneration I
    • Presenter:William Freeman, MD

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 15,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what it is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


Lisa DeFrancesco
(862) 261-7152

Mark Marmur
(973) 906-1526

To view the original version on PR Newswire, visit:

SOURCE Allergan plc

PR Newswire

Last updated on: 13/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.